Literature DB >> 18729380

Recognition of cisplatin-DNA interstrand cross-links by replication protein A.

Steve M Patrick1, Kristin Tillison, Jeffrey M Horn.   

Abstract

Replication protein A (RPA) is a heterotrimeric protein that is required for DNA replication and most DNA repair pathways. RPA has previously been shown to play a role in recognizing and binding damaged DNA during nucleotide excision repair (NER). RPA has also been suggested to play a role in psoralen DNA interstrand cross-link (ICL) repair, but a clear biochemical activity has yet to be identified in the ICL DNA repair pathways. Using HeLa cell extracts and DNA affinity chromatography, we demonstrate that RPA is preferentially retained on a cisplatin interstrand cross-link (ICL) DNA column compared with undamaged DNA. The retention of RPA on cisplatin intrastrand and ICL containing DNA affinity columns is comparable. In vitro electrophoretic mobility shift assays (EMSAs) using synthetic DNA substrates and purified RPA demonstrate higher affinity for cisplatin ICL DNA binding compared with undamaged DNA. The enhanced binding of RPA to the cisplatin ICL is dependent on the DNA length. As the DNA flanking the cisplatin ICL is increased from 7 to 21 bases, preferential RPA binding is observed. Fluorescence anisotropy reveals greater than 200-fold higher affinity to a cisplatin ICL containing 42-mer DNA compared with an undamaged DNA and a 3-4-fold higher affinity when compared with a cisplatin intrastrand damaged DNA. As the DNA length and stringency of the binding reaction increase, greater preferential binding of RPA to cisplatin ICL DNA is observed. These data are consistent with a role for RPA in the initial recognition and initiation of cisplatin ICL DNA repair.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729380     DOI: 10.1021/bi800460d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Novel role of base excision repair in mediating cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Venkata Srinivas Mohan Nimai Dangeti; Ashley R Brown; Lauren A Banze; Xiao-Hong Wang; Robert W Sobol; Steve M Patrick
Journal:  J Biol Chem       Date:  2011-02-28       Impact factor: 5.157

2.  Differential role of base excision repair proteins in mediating cisplatin cytotoxicity.

Authors:  Akshada Sawant; Ashley M Floyd; Mohan Dangeti; Wen Lei; Robert W Sobol; Steve M Patrick
Journal:  DNA Repair (Amst)       Date:  2017-01-11

3.  Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links.

Authors:  Guangyu Zhu; Stephen J Lippard
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

Review 4.  DNA interstrand crosslink repair in mammalian cells: step by step.

Authors:  Parameswary A Muniandy; Jia Liu; Alokes Majumdar; Su-ting Liu; Michael M Seidman
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-02       Impact factor: 8.250

5.  Targeting the OB-Folds of Replication Protein A with Small Molecules.

Authors:  Victor J Anciano Granadillo; Jennifer N Earley; Sarah C Shuck; Millie M Georgiadis; Richard W Fitch; John J Turchi
Journal:  J Nucleic Acids       Date:  2010-12-06

Review 6.  Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts.

Authors:  Gaëlle Savreux-Lenglet; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Int J Mol Sci       Date:  2015-11-05       Impact factor: 5.923

7.  Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Akshada Sawant; Venkata Srinivas Mohan Nimai Dangeti; Robert W Sobol; Steve M Patrick
Journal:  Nucleic Acids Res       Date:  2013-06-12       Impact factor: 16.971

8.  Mitomycin C and decarbamoyl mitomycin C induce p53-independent p21WAF1/CIP1 activation.

Authors:  Shu-Yuan Cheng; Jiwon Seo; Bik Tzu Huang; Tanya Napolitano; Elise Champeil
Journal:  Int J Oncol       Date:  2016-09-23       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.